Pharmaceutical Technology

FEBRUARY 1, 2023

However, caution must be taken, especially while bringing new mAbs to market, to avoid the potentially serious consequences of inducing novel viral mutations and further antibody-resistant strains of RSV. As an RNA virus, like SARS-CoV-2, RSV is highly prone to mutations.

Vaccination 162

Vaccination Vaccine Antibody Protein 162

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. agreed to share equally the costs of development, manufacturing, marketing and commercialization of the products each is developing related to COVID-19, including the hAd5 vaccine candidate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Delveinsight

DECEMBER 13, 2020

The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease. in January 2019.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

SEPTEMBER 8, 2020

About Moderna Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Sanofi, Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

XTalks

NOVEMBER 7, 2022

Exosomes are extracellular vesicles that contain molecular cargoes (such as various proteins, RNAs and DNAs) specific to the origin cell. Also, exosomes are mostly being used for the detection of circulating RNA and microRNA. “An Exosome-Based Liquid Biopsy in Oncology.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815. million and $38.8 million, respectively, as compared to $17.6

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

AUGUST 10, 2022

By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Exactly three decades later, the first CAR T cell therapy hit the market. To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

The Pharma Data

SEPTEMBER 1, 2020

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S. Food and Drug Administration (FDA). Results are ready in only 15 minutes.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Drug Discovery World

NOVEMBER 15, 2022

The libraries contain only the sequences that occur in the human repertoire, rather than randomly generated sequences,” adds Dr Leproust. . They contain all the necessary enzymes for transcription and translation, making it possible to execute the central dogma outside a cell. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

OCTOBER 26, 2023

variant was selected in June and within a few months, both Pfizer-BioNTech and Moderna were able to get vaccines for it to market by September, which Dr. Kierstead says is “astonishingly fast.” The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

The Pharma Data

AUGUST 3, 2021

. – Second-quarter 2021 operating expenses increased 18 percent, driven primarily by higher research and development investments for late-stage assets, as well as higher relative marketing and selling expenses due to pandemic-related spending reductions in 2020. – Second-quarter 2021 earnings per share (EPS) decreased to $1.53

Antibody 52

Antibody Sales Production Development 52

Pfizer

DECEMBER 13, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. For more information, please visit www.PAXLOVID.com. .

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Protein 52

Protein RNA Production Genetics 52

Pfizer

DECEMBER 20, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. For more information, please visit www.PAXLOVID.com.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

AUGUST 31, 2021

Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose ‡ , in the community setting. Peripheral arterial disease, and: Low density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6

Containment 52

Containment Production RNA Medicine 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 23, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Our Commitment to Access. Immunosuppressants: voclosporin.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

JANUARY 6, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

Pfizer

NOVEMBER 2, 2022

The first participant has been dosed in a Phase 1 trial evaluating the safety, tolerability, and immunogenicity of a nucleoside-modified RNA (modRNA)-based combination vaccine approach. Hemagglutinin is a surface protein of the influenza virus which plays a role in the initiation of infection. COMIRNATY® (COVID-19 Vaccine, mRNA).

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

SEPTEMBER 22, 2020

This does not impact marketed Zolgensma ® (onasemnogene abeparvovec) and the company continues to advance its regulatory filings and intravenous clinical studies. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Clinical Development 52

Clinical Development Gene Therapy Development Gene 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. All this cannot begin to explain the weird reality that the stock markets in the US (and elsewhere) are doing just fine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92